Polyautoimmunity in patients with cutaneous lupus erythematosus: A nationwide sex- and age-matched cohort study from Denmark.
autoimmune diseases
cutaneous lupus erythematosus
epidemiology
polyautoimmunity
thyroid autoimmunity
Journal
JAAD international
ISSN: 2666-3287
Titre abrégé: JAAD Int
Pays: United States
ID NLM: 101774762
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
15
07
2023
medline:
9
10
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
epublish
Résumé
Polyautoimmunity is defined as having 2 or more autoimmune diseases. Little is known about polyautoimmunity in patients with cutaneous lupus erythematosus (CLE). To estimate prevalence and 5-year incidence of non-lupus erythematosus (LE) autoimmune diseases in patients with CLE. Patients with CLE were identified In the Danish National Patient Registry and each patient was age- and sex-matched with 10 general population controls. Outcome information on non-LE autoimmune diseases was obtained by register-linkage between Danish National Patient Registry and the National Prescription Register. The risk ratio (RR) for prevalent non-LE autoimmune disease at time of CLE diagnosis was calculated in modified Poisson regression; and hazard ratios (HRs) for incident non-LE autoimmune disease were estimated in Cox regression analyses. Overall, 1674 patients with CLE had a higher prevalence of a non-LE autoimmune disease than the comparators (18.5 vs 7.9%; RR 2.4; 95% CI, 2.1 to 2.6). Correspondingly, the cumulative incidence of a non-LE autoimmune disease during 5 years of follow-up was increased for the patients with CLE: HR 3.5 (95% CI, 3.0 to 4.0). Risk of detection and misclassification bias, mainly pertaining to the CLE group. Patients with CLE had higher prevalence and 5-year cumulative incidence of a non-LE autoimmune disease than the general population.
Sections du résumé
Background
UNASSIGNED
Polyautoimmunity is defined as having 2 or more autoimmune diseases. Little is known about polyautoimmunity in patients with cutaneous lupus erythematosus (CLE).
Objectives
UNASSIGNED
To estimate prevalence and 5-year incidence of non-lupus erythematosus (LE) autoimmune diseases in patients with CLE.
Methods
UNASSIGNED
Patients with CLE were identified In the Danish National Patient Registry and each patient was age- and sex-matched with 10 general population controls. Outcome information on non-LE autoimmune diseases was obtained by register-linkage between Danish National Patient Registry and the National Prescription Register. The risk ratio (RR) for prevalent non-LE autoimmune disease at time of CLE diagnosis was calculated in modified Poisson regression; and hazard ratios (HRs) for incident non-LE autoimmune disease were estimated in Cox regression analyses.
Results
UNASSIGNED
Overall, 1674 patients with CLE had a higher prevalence of a non-LE autoimmune disease than the comparators (18.5 vs 7.9%; RR 2.4; 95% CI, 2.1 to 2.6). Correspondingly, the cumulative incidence of a non-LE autoimmune disease during 5 years of follow-up was increased for the patients with CLE: HR 3.5 (95% CI, 3.0 to 4.0).
Limitations
UNASSIGNED
Risk of detection and misclassification bias, mainly pertaining to the CLE group.
Conclusion
UNASSIGNED
Patients with CLE had higher prevalence and 5-year cumulative incidence of a non-LE autoimmune disease than the general population.
Identifiants
pubmed: 37808964
doi: 10.1016/j.jdin.2023.07.018
pii: S2666-3287(23)00136-0
pmc: PMC10550802
doi:
Types de publication
Journal Article
Langues
eng
Pagination
126-133Informations de copyright
© 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Dr Cordtz is employed at IQVIA outside of this work. Dr Dreyer has received speakers fee from Eli Lilly, Galderma, and Janssen and research grants from BMS (outside the present work). Drs Kofoed, Stensballe, Bliddal, Kristensen, Feldt-Rasmussen, and Nielsen and Authors Graven-Nielsen, Vittrup, Kragh, and Lund have no conflicts of interest to declare.
Références
JAMA Dermatol. 2018 Jun 1;154(6):712-716
pubmed: 29801110
Lupus. 2017 Jan;26(1):48-53
pubmed: 27235406
Clin Exp Rheumatol. 2017 Nov-Dec;35(6):929-935
pubmed: 28770708
Int J Epidemiol. 2017 Jun 1;46(3):798-798f
pubmed: 27789670
Front Immunol. 2020 Jul 02;11:1353
pubmed: 32714331
J Autoimmun. 2017 Jan;76:10-20
pubmed: 27776934
Clin Rheumatol. 2022 Nov;41(11):3525-3536
pubmed: 35907102
Semin Arthritis Rheum. 2020 Feb;50(1):95-127
pubmed: 31526594
Indian Dermatol Online J. 2014 Jan;5(1):7-13
pubmed: 24616847
Nutr J. 2014 Jun 17;13:61
pubmed: 24939238
Lupus. 2014 Apr;23(4):360-9
pubmed: 24449338
Br J Dermatol. 2020 May;182(5):1309-1310
pubmed: 31647114
Front Endocrinol (Lausanne). 2017 Jul 31;8:179
pubmed: 28824542
Int J Rheum Dis. 2019 Mar;22(3):386-391
pubmed: 30548416
Life Sci. 2019 Dec 1;238:116924
pubmed: 31606383
Ethn Dis. 2009 Summer;19(3):301-7
pubmed: 19769013
F1000Res. 2017 Sep 28;6:1776
pubmed: 29043075
Oncotarget. 2017 Jan 3;8(1):268-284
pubmed: 27902485
Arthritis Res Ther. 2009;11(3):229
pubmed: 19519924
Curr Opin Rheumatol. 2007 Jan;19(1):49-54
pubmed: 17143096
Autoimmune Dis. 2012;2012:254319
pubmed: 22454759
Eur J Endocrinol. 2012 Oct;167(4):483-90
pubmed: 22802427
Dermatology. 2022;238(1):92-100
pubmed: 34062538
Mol Med. 2014 Mar 24;20:138-46
pubmed: 24531836
Lupus. 2018 Aug;27(9):1424-1430
pubmed: 29788808
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Eur J Epidemiol. 2014 Aug;29(8):541-9
pubmed: 24965263